CHECKMATE PHARMACEUTICALS IN (CMPI) Forecast, Price Target & Analyst Ratings

NASDAQ:CMPI • US1628181083

Current stock price

10.5
+0.02 (+0.19%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CHECKMATE PHARMACEUTICALS IN (CMPI).

Forecast Snapshot

Consensus Price Target

Price Target
$12.75
+ 21.43% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Aug 10, 2022
Period
Q2 / 2022
EPS Estimate
-$0.77
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
82.50%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$12.75
Upside
+ 21.43%
From current price of $10.50 to mean target of $12.75, Based on 8 analyst forecasts
Low
$6.06
Median
$12.75
High
$19.95

Price Target Revisions

1 Month
N/A
3 Months
N/A

Price Target Summary

8 Wall Street analysts provided a forecast for the next 12 months for CMPI. The average price target is 12.75 null. This implies a price increase of 21.43% is expected in the next year compared to the current price of 10.5.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

CMPI Current Analyst RatingCMPI Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0.5 1 1.5 2 2.5

Analyst Ratings History

CMPI Historical Analyst RatingsCMPI Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8

Analyst Ratings Consensus

ChartMill Buy Consensus
82.50%
CMPI was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about CMPI.
In the previous month the buy percentage consensus was at a similar level.
CMPI was analyzed by 8 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2022-04-20BTIGDowngrade Buy -> Neutral
2021-10-06B of A SecuritiesUpgrade Neutral -> Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
Aug 10, 2022
Period
Q2 / 2022
EPS Estimate
-$0.77
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
13.07%
Number of Analysts
4

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A

Next Earnings Summary

CMPI is expected to report earnings on 8/10/2022. The consensus EPS estimate for the next earnings is -0.76 null and the consensus revenue estimate is 0 null.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2018 2019 2020 2021 2022 2023 2024 2025 2026
Revenue
YoY % growth
CMPI revenue by date.CMPI revenue by date.
N/AN/AN/AN/A
2.94%		N/A
5.00%
EBITDA
YoY % growth
CMPI ebitda by date.CMPI ebitda by date.
N/AN/AN/A-61.4MN/AN/AN/AN/AN/A
EBIT
YoY % growth
CMPI ebit by date.CMPI ebit by date.
-20.99M-28.89M
-37.64%		-37M
-28.07%		-61.47M
-66.14%		N/AN/AN/AN/AN/A
Operating Margin
CMPI operating margin by date.CMPI operating margin by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
CMPI eps by date.CMPI eps by date.
N/AN/AN/A-2.84
14.85%		N/A
-8.64%		N/A
24.63%		N/A
-87.28%		N/A
32.67%		N/A
31.33%

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q2 / 22 Q3 / 22 Q4 / 22 Q1 / 23 Q2 / 23 Q3 / 23 Q4 / 23
EPS
Q2Q % growth		-0.77
13.07%		-0.76
-10.13%		-0.79
-26.68%		-0.78
-6.19%		-0.78
-1.33%		-0.77
-0.67%		-0.77
2.60%
Revenue
Q2Q % growth
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		N/AN/AN/AN/AN/AN/AN/A

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

CMPI Yearly Revenue VS EstimatesCMPI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 10M 20M 30M 40M 50M
CMPI Yearly EPS VS EstimatesCMPI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3 -4

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
-15.32%
EPS Next 5 Year
5.24%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

CHECKMATE PHARMACEUTICALS IN / CMPI Forecast FAQ

What do analysts expect the price target to be for CHECKMATE PHARMACEUTICALS IN (CMPI)?

8 analysts have analysed CMPI and the average price target is 12.75 null. This implies a price increase of 21.43% is expected in the next year compared to the current price of 10.5.

What is the next earnings date for CMPI stock?

CHECKMATE PHARMACEUTICALS IN (CMPI) will report earnings on 2022-08-10.

What are the consensus estimates for CMPI stock next earnings?

The consensus EPS estimate for the next earnings of CHECKMATE PHARMACEUTICALS IN (CMPI) is -0.76 null and the consensus revenue estimate is 0 null.

How do analysts rate CHECKMATE PHARMACEUTICALS IN (CMPI)?

The consensus rating for CHECKMATE PHARMACEUTICALS IN (CMPI) is 82.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.